Donald Trump Mentioned Hydroxychloroquine and Chloroquine
US President Donald Trump tweeted about the inefficiency of drugs hydroxychloroquine, which was recently taken by him, and chloroquine in the COVID 19 treatment today. he shared the post of twitter moments along with the title “Many doctors and studies disagree with this!”
The FDA said Monday that the drugs hydroxychloroquine and chloroquine are “unlikely to be effective” in treating the coronavirus, revoking emergency authorization of the two malaria drugs previously endorsed by President Trump. the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate donated to the Strategic National Stockpile to be used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation in a clinical trial was not feasible. Donald Trump also quoted
The agency determined that the legal criteria for issuing a EUA are no longer met. Based on its ongoing analysis of the EUA and emerging scientific data, the FDA determined that chloroquine and hydroxychloroquine are unlikely to be effective in treating COVID-19 for the authorized uses in the EUA. Additionally, in light of ongoing serious cardiac adverse events and other potentially serious side effects, the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks for the authorized use.
This is the statutory standard for issuance of a EUA. The Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services originally requested the EUA covering chloroquine and hydroxychloroquine, and the FDA granted the EUA on March 28, 2020, based on the science and data available at the time. Today, in consultation with the FDA, BARDA sent a letter to the FDA requesting revocation of the EUA based on up to date science and data. Food and drug administration said on its press release on July 15.
FDA Deputy Commissioner for Medical and Scientific Affairs Anand Shah, M.D said,“We’ve made clear throughout the public health emergency that our actions will be guided by science and that our decisions may evolve as we learn more about the SARS-CoV-2 virus, review the latest data, and consider the balance of risks versus benefits of treatments for COVID-19”.
Donald Trump widely faced criticism after the mass importing of these medications from India.